Liege

• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease Ended
  2024-511115-25-00 4 2022-11-21 chronic pulmonary sarcoidosis
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• A prospective interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of … Ended
  2024-516816-72-00 5 2022-04-27 preeclampsia
• A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended
  2024-514336-24-00 5 2022-03-24 Familial Chylomicronemia Syndrome (FCS)
• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)
• A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ended
  2022-501686-47-00 7 2022-02-28 relapsed/refractory chronic lymphocytic leukemia relapsed/refractory s
• Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended
  2023-508820-37-00 5 2022-02-03 Cytomegalovirus Infection (CMV)
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20 Chronic Obstructive Pulmonary Disease (COPD)
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
• Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment Ended
  2024-511189-36-00 4 2021-12-23 Non-small cell lung cancer (NSCLC)
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended
  2024-510762-16-00 4 2021-11-30 Metastatic head and neck squamous cell carcinoma (HNSCC)

Showing 577–600 of 639 trials